SPATA13 Antibody

What is SPATA13 and why is it significant in research?

SPATA13 (Spermatogenesis Associated Protein 13), also known as ASEF2 (Adenomatous polyposis coli-stimulated guanine nucleotide exchange factor 2), is a multifunctional protein with significant research interest. It has been identified as a causative gene for primary angle-closure glaucoma (PACG) through genetic linkage and whole genome sequencing studies . SPATA13 enables guanyl-nucleotide exchange factor (GEF) activity and is involved in critical cellular processes including cell migration and plasma membrane projection assembly . The protein is expressed in various ocular tissues, including ciliary epithelia, iris sphincter and dilator muscles, corneal epithelium, and retinal layers, making it particularly relevant for ophthalmic research . Additionally, it plays crucial roles in sperm maturation and fertility, positioning it as an important target in reproductive biology research .

What are the known isoforms of SPATA13 and how do they differ?

SPATA13 exists in multiple isoforms, with the two primary variants being:

• SP-1277 (SPATA13 isoform I): The full-length 1277-residue protein that localizes to the nucleus with partial co-localization with nuclear speckles. During mitosis, this isoform becomes part of the kinetochore complex .

• SP-652: A shorter isoform that has been implicated in actin function .

These isoforms can be distinguished using specific antibodies. N-terminal antibodies recognize SP-1277 but show no reactivity with SP-652, while C-terminal antibodies recognize all SPATA13 isoforms . When analyzed by Western blot, SP-1277 appears as a band of approximately 166kDa, while SP-652 appears at approximately 100kDa . The differential localization and function of these isoforms suggest they may have distinct roles in cellular processes.

What is the cellular and tissue distribution of SPATA13?

SPATA13 shows diverse expression patterns across tissues and cellular compartments:

Immunohistochemistry studies on both murine and human eye sections have confirmed SPATA13 expression in these ocular tissues . At the subcellular level, SPATA13 displays both nuclear and cytoplasmic localization, with the nuclear staining appearing predominantly grainy in pattern .

What are the validated applications for SPATA13 antibodies in research?

SPATA13 antibodies have been validated for multiple research applications:

• Western Blot (WB): For detecting SPATA13 isoforms in cell or tissue lysates. The N-terminal antibodies recognize SP-1277 specifically, while C-terminal antibodies recognize all SPATA13 isoforms .

• Immunofluorescence (IF): For visualizing the cellular localization of SPATA13. This technique has revealed both nuclear and cytoplasmic distributions of the protein .

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of SPATA13 in research samples .

• Immunohistochemistry (IHC): Successfully used on both murine and human eye sections to demonstrate SPATA13 expression in various ocular tissues .

When selecting an antibody for these applications, researchers should consider whether they need to detect all SPATA13 isoforms (using C-terminal antibodies) or specifically SP-1277 (using N-terminal antibodies) .

How should researchers validate SPATA13 antibody specificity for their experiments?

Validation of SPATA13 antibody specificity is crucial for obtaining reliable research results. Based on published methodologies, researchers can follow these steps:

• Cloning and Expression Controls: Clone the SPATA13 isoforms (SP-1277, SP-652) and fragments (such as N-terminal portions) as fusion proteins (e.g., with AcGFP) and express them in cell lines like HT1080 or RPE-1 .

• Western Blot Validation: Perform Western blot analysis using the expressed fusion proteins and compare reactivity patterns with the antibody in question. For instance, N-terminal antibodies should recognize SP-1277 but not SP-652 .

• Immunofluorescence Cross-Validation: Transfect cells with tagged SPATA13 constructs (e.g., AcGFP-SPATA13) and perform immunostaining with the antibody. Colocalization of the tag signal with antibody staining confirms specificity .

• Tissue Expression Patterns: Compare antibody reactivity patterns in tissues with known SPATA13 expression, such as eye tissues for N-terminal antibodies .

This multi-approach validation ensures that antibodies are specifically detecting SPATA13 rather than cross-reacting with other proteins.

How can researchers effectively detect the subcellular localization of SPATA13?

To effectively detect SPATA13's subcellular localization, researchers should employ:

• Immunofluorescence with Specific Antibodies: Both N- and C-terminal SPATA13 antibodies have shown predominantly grainy nuclear staining in RPE-1 cells, with additional cytoplasmic signals .

• Co-localization Studies: For detailed characterization, co-stain with:

  • Nuclear markers (e.g., DAPI for DNA)

  • Nuclear speckle markers (as SPATA13 partially co-localizes with nuclear speckles)

  • Kinetochore markers (e.g., polo-like kinase 1 (PLK-1) and centrosome-associated protein E (CENP-E)) during mitosis

  • Actin markers (using phalloidin) to investigate potential cytoskeletal associations

• Live Cell Imaging: For dynamic studies, transfect cells with tagged constructs (e.g., AcGFP-SPATA13) to observe localization changes during the cell cycle .

• Nuclear Actin Visualization: Using nuclear actin chromobody (nAC) probes in combination with SPATA13 immunostaining can help determine if SPATA13 associates with nuclear actin structures .

How can researchers address cross-reactivity issues when using SPATA13 antibodies?

Cross-reactivity is a common challenge with antibodies. For SPATA13 antibodies specifically:

• Isoform Specificity: Western blots have shown that C-terminal antibodies can recognize multiple bands (70kDa and 80-180kDa range), while N-terminal antibodies from different sources show variable patterns . To address this:

  • Use N-terminal antibodies when specifically targeting SP-1277

  • Validate with recombinant protein controls

  • Consider pre-absorption with recombinant proteins to improve specificity

• Background Reduction: In immunostaining applications, optimize by:

  • Testing multiple antibody dilutions (recommended dilutions may vary by application and vendor)

  • Performing proper blocking steps (BSA or serum from the species of the secondary antibody)

  • Including appropriate negative controls (e.g., samples from SPATA13 knockout models or cells treated with SPATA13 siRNA)

• Multiple Antibody Approach: To increase confidence in results, use antibodies from different sources or targeting different epitopes, and compare the patterns obtained .

What controls should be included when studying SPATA13 mutations in primary angle closure glaucoma?

When investigating SPATA13 mutations in PACG research:

• Genotyping Controls:

  • Include known positive controls (samples with confirmed mutations, e.g., the 9 bp deletion c.1432_1440del; p.478_480del)

  • Include negative controls (confirmed wild-type samples)

  • Consider population-matched controls to account for ethnic variations in PACG prevalence

• Functional Validation Controls:

  • Wild-type SPATA13 expression constructs

  • Mutant SPATA13 constructs (with specific mutations found in PACG patients)

  • Vector-only controls

  • GEF activity assays with appropriate positive and negative controls, as mutations have been shown to increase RAC1-dependent GEF activity

• Family Segregation Analysis:

  • When possible, analyze multiple affected and unaffected family members to confirm co-segregation of mutations with disease phenotype

  • Address variable expression and incomplete penetrance issues by careful phenotyping

How might SPATA13's roles in kinetochore function and mitosis impact ocular tissue homeostasis?

SPATA13's localization to kinetochores during mitosis suggests a potential role in cell division regulation . This function may have significant implications for ocular tissue homeostasis:

• Cell Division Regulation: SPATA13 co-localizes with kinetochore markers polo-like kinase 1 (PLK-1) and centrosome-associated protein E (CENP-E) during mitosis . Proper kinetochore assembly and function are crucial for chromosome segregation.

• Tissue Homeostasis Hypothesis: The identified mutations in PACG patients increase GEF activity , which could potentially:

  • Disrupt normal mitotic progression in ocular tissues with high SPATA13 expression

  • Alter cell proliferation rates or lead to aneuploidy

  • Affect tissue architecture and function over time

• Research Approaches:

  • Live cell imaging of fluorescently tagged SPATA13 during mitosis in ocular cell types

  • Analysis of chromosome segregation errors in cells expressing PACG-associated SPATA13 mutations

  • Investigation of tissue-specific effects in transgenic animal models

Understanding this connection could provide new insights into the pathogenesis of PACG and potentially identify novel therapeutic targets.

What are the proposed mechanisms linking SPATA13 mutations to primary angle closure glaucoma pathogenesis?

Several mechanisms have been proposed linking SPATA13 mutations to PACG:

• Altered GEF Activity: The 9 bp deletion (c.1432_1440del; p.478_480del) and three other variants identified in PACG patients increase RAC1-dependent GEF activity . This dysregulation may affect:

  • Cytoskeletal dynamics and cell morphology

  • Cell migration and tissue remodeling

  • Intercellular junctions and tissue architecture

• Tissue Homeostasis Disruption: SPATA13 is highly expressed in ocular tissues affected in PACG, including ciliary epithelia and iris . Mutations may disrupt homeostasis in these tissues, potentially contributing to:

  • Alterations in anterior chamber angle development or maintenance

  • Changes in aqueous humor production or drainage

  • Structural abnormalities predisposing to angle closure

• Potential Interaction with Other PACG-Associated Genes: SPATA13 may interact with other genes previously associated with PACG, such as:

  • MFRP (membrane type frizzled related protein)

  • eNOS (endothelial nitric oxide synthase)

  • MMP9 (matrix metalloproteinase-9)

Future research investigating these mechanisms could include protein interaction studies, transcriptomic analyses of mutant effects, and development of animal models expressing PACG-associated SPATA13 variants.

How might the dual roles of SPATA13 in reproductive biology and ocular pathology be integrated in a research program?

SPATA13's involvement in both sperm maturation/fertility and ocular pathology presents unique opportunities for integrated research:

• Comparative Tissue Expression and Regulation:

  • Analyze tissue-specific expression patterns and regulation of SPATA13 isoforms

  • Identify common signaling pathways between reproductive and ocular tissues

  • Investigate whether reproductive and ocular phenotypes co-segregate in families with SPATA13 mutations

• Shared Cellular Mechanisms:

  • Both reproductive and ocular functions may involve SPATA13's role in:

    • Cytoskeletal regulation

    • Cell migration

    • Specialized cell junctions

  • Research could focus on these shared cellular processes

• Methodological Integration:

  • Transgenic models could be examined for both ocular and reproductive phenotypes

  • High-throughput screening for small molecule modulators of SPATA13 function could benefit both research areas

  • Insights from one field may inform experimental design in the other

This integrated approach could accelerate discovery and provide unexpected insights into both PACG pathogenesis and reproductive biology.

What are the most promising future directions for SPATA13 antibody-based research?

Several promising research directions emerge from current understanding of SPATA13:

• Diagnostic Applications:

  • Development of standardized immunohistochemical protocols for SPATA13 detection in ocular tissues

  • Exploration of SPATA13 as a biomarker for PACG risk or progression

  • Creation of mutation-specific antibodies to detect disease-associated variants

• Therapeutic Target Validation:

  • Use of SPATA13 antibodies to screen for compounds that modulate its GEF activity

  • Investigation of SPATA13's role in signaling networks that could be targeted therapeutically

  • Development of antibody-based inhibitors of specific SPATA13 functions

• Fundamental Biology:

  • Further characterization of SPATA13's role in kinetochore function and mitotic regulation

  • Investigation of potential non-canonical functions in the nucleus

  • Cross-species comparative studies to understand evolutionary conservation of SPATA13 functions